Published on 28/12/2025
How Data Localization Laws Shape Multinational Clinical Trials in China
Introduction
China’s data localization laws are reshaping the way multinational sponsors design and execute clinical trials in the country. Under the Cybersecurity Law (2017), the Data Security Law (2021), and the Personal Information Protection Law (PIPL, 2021), patient data generated in China must be stored domestically, with strict controls on cross-border transfers. For clinical trials, these requirements extend to trial master files (TMFs), electronic data capture (EDC) systems, and genomic data overseen by the Human Genetic Resources Administration of China (HGRAC). While these laws aim to protect patient privacy and national interests, they create operational and compliance challenges for global sponsors integrating Chinese data into multinational submissions. This article examines the impact of China’s data localization laws on clinical trials, highlighting regulatory requirements, practical challenges, and strategies for compliance.
Background and Regulatory Framework
Cybersecurity and Data Security Laws
China’s Cybersecurity Law (2017) requires that all personal data collected within China be stored locally. The Data Security Law (2021) expanded these requirements, introducing classifications of data importance and imposing strict security assessments for cross-border transfers. Clinical trial data falls under “important data,” requiring additional approvals.
Personal
The PIPL governs the collection, processing, and storage of personal information, including patient health records from clinical trials. Sponsors must obtain explicit informed consent for data use and ensure local storage. Transfers abroad require security assessments by Chinese regulators.
Case Example: Genomic Data and HGRAC
Clinical trials involving genetic materials are regulated by HGRAC. Exporting genomic data or samples requires approval, and in many cases, raw data must remain in China. A rare disease trial in 2021 was delayed by six months while HGRAC reviewed data export requests, highlighting the impact of localization rules.
Core Clinical Trial Insights
Impact on Multinational Clinical Trials
Data localization laws complicate the integration of Chinese trial data into global submissions. Sponsors must establish local servers for EDC and TMF systems, often duplicating infrastructure. Cross-border data transfer for FDA or EMA submissions requires anonymization, regulatory approvals, and secure transfer protocols.
Compliance Challenges for Sponsors
Sponsors face challenges including:
✔️ Increased costs for local data infrastructure
✔️ Delays in cross-border transfer approvals
✔️ Complex HGRAC procedures for genetic data
✔️ Need for local CROs with validated IT systems
✔️ Training staff on data privacy obligations under PIPL
Failure to comply can result in penalties, trial delays, or invalidation of data.
Role of CROs and Local Partnerships
CROs with established local IT systems and regulatory expertise are critical for compliance. Local CROs provide validated platforms for data storage and ensure compatibility with NMPA submission systems. Sponsors increasingly rely on hybrid CRO models to bridge global and local requirements.
Data Integrity and Inspection Readiness
The NMPA conducts inspections to ensure trial data is stored domestically and meets audit trail requirements. Sponsors must demonstrate that local systems are validated, secure, and accessible to inspectors. Non-compliance can trigger warnings or rejection of trial data.
Integration of Real-World Evidence (RWE)
RWE studies in China also fall under data localization laws. Hospital-based electronic health records must be stored locally, with export requiring regulator approval. This affects multinational use of RWE in regulatory submissions and post-market commitments.
Best Practices & Preventive Measures
Sponsors should:
✔️ Establish local servers for trial data and TMF systems
✔️ Partner with CROs with validated local IT infrastructure
✔️ Train staff on PIPL and HGRAC requirements
✔️ Plan early for cross-border transfer approvals
✔️ Use anonymization and encryption to reduce compliance risks
✔️ Engage with regulators proactively on sensitive data issues
These practices reduce delays and ensure data acceptance for global submissions.
Scientific & Regulatory Evidence
China’s framework is based on the Cybersecurity Law, Data Security Law, PIPL, and HGRAC regulations. These align partially with EU GDPR principles but emphasize national data sovereignty. WHO GCP requires data integrity and confidentiality, both supported by localization rules. Comparative evidence shows China’s laws are stricter than those in the U.S. or EU, requiring additional sponsor planning.
Special Considerations
Decentralized trials face added complexity, as wearable devices and eConsent systems must store data locally. Rare disease and genomic studies require HGRAC approvals, which can extend timelines. Multinational sponsors must align global IT systems with local requirements, often duplicating infrastructure.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult the NMPA and HGRAC early in protocol development to clarify data localization obligations. Regulatory advice is particularly important for genomic data, multinational submissions, and decentralized trial models. Early engagement helps mitigate delays and ensures compliance.
Case Studies
Case Study 1: Oncology Trial Data Integration
A multinational oncology sponsor established local servers in China to store trial data. Cross-border transfers for FDA submission were anonymized and approved after a security assessment, avoiding delays. This case illustrates the importance of infrastructure planning for multinational submissions.
Case Study 2: Rare Disease Trial and HGRAC Approval
A rare disease sponsor faced delays due to HGRAC restrictions on exporting genetic data. By redesigning the study to analyze genomic data within China and exporting only aggregated results, the sponsor achieved compliance and avoided further delays.
FAQs
1. What are China’s data localization laws?
They require patient and clinical trial data generated in China to be stored domestically, with strict rules for cross-border transfers.
2. How do these laws affect multinational clinical trials?
They complicate data integration, requiring local servers, CRO partnerships, and regulator approvals for global submissions.
3. What role does HGRAC play?
HGRAC regulates genetic data and sample use, requiring approval for export. Many genomic datasets must remain in China.
4. How can sponsors ensure compliance?
By using validated local IT infrastructure, anonymizing data, training staff on PIPL, and engaging regulators early for approvals.
5. Are decentralized trials affected?
Yes, devices and eConsent platforms must store data locally, adding complexity to hybrid or decentralized trial models.
6. How do China’s laws compare globally?
They are stricter than U.S. and EU standards, with stronger emphasis on national sovereignty and regulator-controlled transfers.
Conclusion & Call-to-Action
China’s data localization laws have fundamentally reshaped the clinical trial landscape, introducing stricter controls on patient data storage and cross-border transfers. For multinational sponsors, compliance requires careful planning, investment in local infrastructure, and proactive regulatory engagement. While these laws present operational challenges, they also reinforce patient privacy and data integrity. Organizations planning trials in China must integrate data localization strategies into feasibility and submission planning to ensure compliance, avoid delays, and maintain global data integrity.